Dinutuximab Can Be Delivered During Induction Without Breaking the Regimen

Children with high-risk neuroblastoma may be able to receive dinutuximab earlier in frontline therapy than has traditionally been done, without losing dose delivery or triggering prohibitive toxicity. In a Children’s Oncology Group pilot study, the anti-GD2 antibody was added to induction chemotherapy cycles 3 through 5, testing whether chemoimmunotherapy could be integrated before consolidation rather than reserved for later phases of treatment.

The appeal of that strategy is biological as well as clinical. Neuroblastoma expresses GD2, making it a direct target for antibody-based immune killing, and earlier exposure could theoretically engage residual tumor burden before resistant clones become dominant. The concern has always been whether the inflammatory and pain-related toxicities associated with dinutuximab would interfere with the intensity and timing of curative induction therapy. Here, the regimen moved through the induction window with no unacceptable toxicities and no toxic deaths during the dinutuximab-containing cycles.

Trial Delivery Held Up Across Eight Sites

COG ANBL17P1 was a prospective, single-arm, limited-institution pilot study conducted at eight sites from January 2019 through June 2020. Forty eligible, evaluable patients with newly diagnosed HRNBL were enrolled. The study specifically examined tolerability, defined by predefined unacceptable toxicity or toxic death during dinutuximab-containing cycles, and feasibility, defined by the ability to receive at least 75% of planned dinutuximab doses.

The delivery metrics were reassuring. Patients received 92.0% to 101.8% of intended induction dinutuximab doses, meeting the feasibility target. Grade 3 or higher dinutuximab-related toxicities during cycles 3 to 5 were most often fever, occurring in 30.0% of patients, and pain, occurring in 7.5%. Those adverse events fit the known toxicity profile of anti-GD2 therapy, which can provoke cytokine-mediated fever and neuropathic pain through immune activation against ganglioside-expressing tissue. The key point is that those effects did not derail treatment delivery at the group level.

No patient experienced an unacceptable toxicity or toxic death during the dinutuximab-containing induction cycles.

Response Signals Emerged Before Consolidation

Among the 37 patients who completed end-of-induction assessments, 13 achieved a complete response, 22 achieved a partial response, one had a minor response, none had stable disease, and one had progressive disease. The combined end-of-induction complete response plus partial response rate was 87.5%. For a population defined by biologically aggressive disease, that response distribution suggests the regimen preserved antitumor activity while the antibody was introduced earlier in therapy.

Still, response depth at induction cannot be interpreted as proof of long-term benefit. Neuroblastoma relapse biology remains unforgiving, and early radiographic or marrow response does not always translate into durable control once minimal residual disease and treatment-resistant subclones are considered. Even so, the ability to obtain substantial disease regression while maintaining dose intensity matters because induction is when many frontline regimens are most vulnerable to cumulative toxicity, organ dysfunction, and schedule drift.

Toxicity Pattern Matched the Known Anti-GD2 Profile

The adverse events observed during cycles 3 through 5 look familiar to anyone who has managed anti-GD2 therapy: fever, pain, and the practical burden of delivering an immunologically active monoclonal antibody alongside cytotoxic agents. Fever was the most common grade 3 or higher event, and pain followed behind. Neither signal was unexpected, but the absence of toxic death and the absence of predefined unacceptable toxicity are clinically meaningful because they address the central question of whether dinutuximab can be moved earlier without overwhelming families, bedside teams, or infusion infrastructure.

For pediatric oncology teams, feasibility is not a soft endpoint. If a regimen cannot be delivered on time and at planned dose, the efficacy seen in a pilot setting becomes hard to reproduce in broader practice. Here, the induction schedule survived contact with real-world pediatric toxicity management across multiple institutions, which supports further testing rather than immediate abandonment.

Why Earlier Immune Therapy Could Matter in Neuroblastoma

The sequencing of anti-GD2 therapy may influence how much residual disease remains available for immune clearance. Induction chemotherapy can reduce bulk and lower the tumor burden that suppresses immune effector function, while dinutuximab can engage antibody-dependent cellular cytotoxicity against remaining GD2-expressing cells. In theory, that combination could create a tighter window of tumor debulking followed by immune pressure, rather than waiting until later phases when marrow reserve is thinner and the immune environment may be more compromised.

The 3-year event-free survival estimate of 52.5% ± 7.9% offers context, but it should be read as a pilot-stage outcome rather than a definitive efficacy claim. A single-arm feasibility study is not designed to determine whether earlier dinutuximab improves survival over standard sequencing. It does show, however, that the regimen can be delivered with acceptable acute safety and without obvious loss of antitumor activity during induction.

The Phase III Question Now Becomes Comparative Benefit

This study clears an important operational hurdle, but it does not settle whether induction chemoimmunotherapy should become the new standard. The next question is comparative: does earlier dinutuximab improve survival, deepen response, or reduce relapse enough to justify the added complexity of frontline administration? A randomized phase III trial is already evaluating the approach, and that study will need to determine whether the feasibility seen here translates into meaningful clinical advantage.

For now, the strongest message is narrow and concrete. Dinutuximab given during induction cycles 3 to 5 was feasible, tolerable, and compatible with planned chemotherapy delivery in children with newly diagnosed high-risk neuroblastoma. The open question is not whether the regimen can be given. It is whether giving it earlier changes the disease course enough to matter for long-term cure.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by Journal of Clinical Oncology (JCO).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA